Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

TKM-100802

Oligonucleotide (siRNA) · developed by Arbutus Biopharma

Phase 1 Most advanced trial (none active)
ABUS Developer
1 Registered trials

What is TKM-100802?

TKM-100802 is a siRNA therapeutic targeting the Ebola virus RNA polymerase L protein. It is designed to silence viral gene expression and reduce viral replication in Ebola virus infection.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Oligonucleotide (siRNA)
Therapy area
Infectious disease
Developer
Arbutus Biopharma Corporation (ABUS)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT02041715 Phase 1 Ebola Virus Infection Terminated ABUS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Ebola Virus Infection

More from Arbutus Biopharma

AB-836 Phase 1 ARB-001467 Phase 2 Imdusiran Phase 2 Peg-IFNα-2a Phase 2 PRO-040201 Phase 1 TKM-100201 Phase 1 TKM-PLK1 Phase 1/2

Follow ABUS, the company behind TKM-100802

See ABUS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ABUS catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.